Tech Company Financing Transactions
PreciseDx Funding Round
PreciseDx, operating out of New York, secured $10.8 million from Merck Global Health Innovation Fund, Agilent Technologies and Hobart Group Capital SA.
Transaction Overview
Company Name
Announced On
1/26/2022
Transaction Type
Venture Equity
Amount
$10,750,000
Round
Series A
Investors
Merck Global Health Innovation Fund (Lead Investor) (David Rubin)
Mount Sinai Ventures (Erik Lium)
Proceeds Purpose
The funding will be used to support the development and commercialization of additional cancer diagnostics and clinical trial testing.
Company Information
Company Status
Private & Independent
Industry
Artificial Intelligence
Mailing Address
1111 Amsterdam Stuyvesant Building 8-822
New York, NY 10025
USA
New York, NY 10025
USA
Phone
Website
Email Address
Overview
Our mission is to democratize access to high-quality medical care and information, regardless of the institution or its geographical location. PreciseDx augments current oncology diagnostics and provides an objective review of each patient's risk, eliminating any subjectivity in the review of patient results.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Carlos Cordon-Cardo
Chief Executive Officer
Wayne Brinster
Chief Medical Officer
Michael Donovan
Chief Scientific Officer
Gerardo Fernandez
Chief Technical Officer
Jack Zeineh
VP - Finance
Andrew Borsanyi
Browse more venture capital transactions:
Prev: 1/26/2022: Rooter venture capital transaction
Next: 1/26/2022: Gr4vy venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC transactions reported here come from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs